An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties.
Di Nitto C, Gilardoni E, Mock J, Nadal L, Weiss T, Weller M, Seehusen F, Libbra C, Puca E, Neri D, De Luca R.
Di Nitto C, et al. Among authors: de luca r.
Pharmaceutics. 2023 Jan 22;15(2):377. doi: 10.3390/pharmaceutics15020377.
Pharmaceutics. 2023.
PMID: 36839699
Free PMC article.